Create your account for 2 FREE subscriber-only articles each month.
Get Free Access Now .
Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.
Stay connected to what's important in medical research and clinical practice Subscribe to the most trusted and influential source of medical knowledge Already a subscriber?
Renew or Sign in Subscribe or Renew Selected specialties View all specialties Selected Topics View all topics Selected Multimedia View all multimedia Current Issue Recent Issues Browse full issue index Recently Published Articles Browse recently published View all learning/CME Other NEJM Group Learning Subscribe or Renew This article is available to subscribers.
Subscribe now .
Already have an account?
Sign in Correspondence Free Preview To the Editor: Arslanian et al. (Aug. 4 issue) 1 report that a once-weekly subcutaneous injection of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, at a dose of 0.75 mg or 1.5 mg was superior to placebo in improving blood glucose control in overweight pediatric patients (10 to <18 years of age) with type 2 diabetes.
Notably, 40% of the children were under 14 years of age.
The average height of the children was 162.4±9.2 cm, which suggests that they had not yet reached their adult height.
A previous study 2 of GLP-1 receptor agonists showed their potential role in an increase . . .
Select an option below: Are you a member of an institution such as a university or hospital?
Learn more about Institutional Access October 20, 2022 N Engl J Med 2022; 387:1529-1531 DOI: 10.1056/NEJMc2211623 Print Subscriber?
Activate your online access.